Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis by Coombes, Jason D et al.
 
 
Osteopontin is a proximal effector of leptin-
mediated non-alcoholic steatohepatitis (NASH)
fibrosis
Coombes, Jason D; Choi, Steve S; Swiderska-Syn, Marzena; Manka, Paul; Reid, Danielle T;
Palma, Elena; Briones-Orta, Marco A; Xie, Guanhua; Younis, Rasha; Kitamura, Naoto; Della
Peruta, Marco; Bitencourt, Shanna; Dollé, Laurent; Oo, Ye Htun; Mi, Zhiyong; Kuo, Paul C;
Williams, Roger; Chokshi, Shilpa; Canbay, Ali; Claridge, Lee
DOI:
10.1016/j.bbadis.2015.10.028
License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Coombes, JD, Choi, SS, Swiderska-Syn, M, Manka, P, Reid, DT, Palma, E, Briones-Orta, MA, Xie, G, Younis,
R, Kitamura, N, Della Peruta, M, Bitencourt, S, Dollé, L, Oo, YH, Mi, Z, Kuo, PC, Williams, R, Chokshi, S,
Canbay, A, Claridge, LC, Eksteen, B, Diehl, AM & Syn, W-K 2016, 'Osteopontin is a proximal effector of leptin-
mediated non-alcoholic steatohepatitis (NASH) fibrosis', Biochimica et Biophysica Acta, vol. 1862, no. 1, pp.
135-144. https://doi.org/10.1016/j.bbadis.2015.10.028
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
After an embargo period this document is subject to the terms of a Creative Commons Attribution Non-Commercial No Derivatives license
Checked Feb 2016
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
  	

Osteopontin is a proximal effector of leptin-mediated non-alcoholic steato-
hepatitis (NASH) fibrosis
Jason D. Coombes, Steve S. Choi, Marzena Swiderska-Syn, Paul P.
Manka, Danielle Reid, Elena Palma, Marco A. Briones-Orta, Guanhua Xie,
Rasha Younis, Naoto Kitamura, Marco della Peruta, Shanna Bitencourt,
Laurent Dolle´, Ye Htun Oo, Zhiyong Mi, Paul C. Kuo, Roger Williams, Shilpa
Chokshi, Ali Canbay, Lee C. Claridge, Bertus Eksteen, Anna Mae Diehl,
Wing-Kin Syn
PII: S0925-4439(15)00328-2
DOI: doi: 10.1016/j.bbadis.2015.10.028
Reference: BBADIS 64356
To appear in: BBA - Molecular Basis of Disease
Received date: 5 August 2015
Revised date: 20 October 2015
Accepted date: 29 October 2015
Please cite this article as: Jason D. Coombes, Steve S. Choi, Marzena Swiderska-Syn,
Paul P. Manka, Danielle Reid, Elena Palma, Marco A. Briones-Orta, Guanhua Xie,
Rasha Younis, Naoto Kitamura, Marco della Peruta, Shanna Bitencourt, Laurent Dolle´,
Ye Htun Oo, Zhiyong Mi, Paul C. Kuo, Roger Williams, Shilpa Chokshi, Ali Canbay, Lee
C. Claridge, Bertus Eksteen, Anna Mae Diehl, Wing-Kin Syn, Osteopontin is a proximal
eﬀector of leptin-mediated non-alcoholic steatohepatitis (NASH) ﬁbrosis, BBA - Molecular
Basis of Disease (2015), doi: 10.1016/j.bbadis.2015.10.028
This is a PDF ﬁle of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its ﬁnal form. Please note that during the production process
errors may be discovered which could aﬀect the content, and all legal disclaimers that
apply to the journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
1 
 
Osteopontin is a proximal effector of leptin-mediated non-alcoholic 
steatohepatitis (NASH) fibrosis 
Authors: 
Jason D. Coombes1, 2, Steve S. Choi3, 4, Marzena Swiderska-Syn3, Paul P. Manka1, 
5, Danielle Reid6, Elena Palma2, 7, Marco A. Briones-Orta1, 2, Guanhua Xie3, Rasha 
Younis1, Naoto Kitamura1, Marco della Peruta7, Shanna Bitencourt8, Laurent Dollé8, 
Ye Htun Oo9, Zhiyong Mi10, Paul C. Kuo10, Roger Williams1, 2, Shilpa Chokshi2, 7, Ali 
Canbay5, Lee C. Claridge11, Bertus Eksteen6, Anna Mae Diehl3, Wing-Kin Syn1, 2, 9, 12, 
13* 
*Senior and corresponding author 
 
Affiliations: 
1Regeneration and Repair Group, The Institute of Hepatology, Foundation for Liver 
Research, London, UK 
2Division of Transplantation Immunology and Mucosal Biology, Kings College 
London, UK 
3Division of Gastroenterology, Department of Medicine, Duke University, NC, USA 
4Section of Gastroenterology, Department of Medicine, Durham Veteran Affairs 
Medical Center, Durham, NC, USA 
5Department of Gastroenterology and Hepatology, Essen University Hospital, Essen, 
Germany 
6Snyder Institute for Chronic Diseases, Health Research and Innovation Centre 
(HRIC), University of Calgary, Canada 
7Viral Hepatitis and Alcohol Research Group, The Institute of Hepatology, 
Foundation for Liver Research, London, UK 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
2 
 
8Liver Cell Biology Lab (LIVR), Department of Cell Biology (CYTO), Faculty of 
Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium 
9Centre for Liver Research and NIHR Birmingham Biomedical Research Unit, 
University of Birmingham, Birmingham, UK 
10Department of Surgery, Loyola University, Chicago, USA 
11Liver Unit, St James University Hospital, Leeds, UK 
12Liver Unit, Barts Health NHS Trust, London, UK 
13Department of Physiology, University of the Basque Country, Bilbao 
 
Running title:  Osteopontin mediates Leptin-associated Fibrogenesis 
Key Words:  fibrosis, hepatic, adipokine, signaling 
Word count: 5479 (including references and figure legends but excluding abstract) 
Corresponding Author: 
Dr Wing-Kin Syn (*) 
Head of Liver Regeneration and Repair 
The Institute of Hepatology 
Foundation for Liver Research 
London WC1E 6HX 
Tel: 44-20272559837 
wsyn@doctors.org.uk 
. 
Disclosures / Competing Interests 
On behalf of authors, I declare no Competing Interests   
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
3 
 
 
Acknowledgement: 
The HSC line (GRX) was a kind gift from Professor J Oliveira (Brazil).  
 
Contributions: 
JDC, SSC, MSS, PM, EP, RY, MAB, GX, NK, LCC, SB, and LD performed 
experiments and contributed intellectually to the study; JDC, SSC, MDP, YHO, RW, 
SC, AMD, ZM, PCK, SC provided samples and reagents, and contributed to funding. 
JDC co-wrote the manuscript. WKS is the lead investigator, who designed and 
supervised the overall project and sub- studies, performed experiments, wrote the 
manuscript, and is the senior author and guarantor of the manuscript. 
 
Funding: 
This study was funded predominantly by CORE-UK (WKS), BRET (WKS), EASL 
(WKS), The Foundation for Liver Research London (WKS), The Polkemmet Trust 
(WKS and RW). Additional funding was provided by the National Institute of Health 
5K08DK080980 (SSC), R01 DK077794 (AMD), Deutsche Forschungsgemeinschaft 
(DFG) CA267/8-1 (AC), DFG MA 6864/1-1 (PPM), and the Wilhelm Lapitz 
Foundation (AC). 
 
Abbreviations: 
NAFLD: nonalcoholic fatty liver disease 
OPN: Osteopontin 
TGF-: transforming growth factor 
SMA: alpha smooth muscle actin 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
4 
 
MCD diet: methionine choline deficient diet 
FFPE: formalin-fixed, paraffin embedded 
HPF: high-powered field 
shScr: short-hairpin RNA against non-target (scrambled) sequence 
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Abstract (250 words): 
 
Introduction: 
Liver fibrosis develops when hepatic stellate cells (HSC) are activated into collagen-
producing myofibroblasts. In non-alcoholic steatohepatitis (NASH), the adipokine 
leptin is upregulated, and promotes liver fibrosis by directly activating HSC via the 
hedgehog pathway. We reported that hedgehog-regulated osteopontin (OPN) plays 
a key role in promoting liver fibrosis. Herein, we evaluated if OPN mediates leptin-
profibrogenic effects in NASH. 
 
Methods: 
Leptin-deficient (ob/ob) and wild-type (WT) mice were fed control or methionine-
choline deficient (MCD) diet. Liver tissues were assessed by sirius-red, OPN and 
SMA IHC, and qRT-PCR for fibrogenic genes. In vitro, HSC with stable OPN (or 
control) knockdown were treated with recombinant (r)leptin and OPN-neutralizing or 
sham-aptamers. HSC response to OPN loss was assessed by wound healing assay. 
OPN-aptamers were also added to precision-cut liver slices (PCLS), and 
administered to MCD-fed WT (leptin-intact) mice to determine if OPN neutralization 
abrogated fibrogenesis. 
 
Results: 
MCD-fed WT mice developed NASH-fibrosis, upregulated OPN, and accumulated 
SMA+ cells. Conversely, MCD-fed ob/ob mice developed less fibrosis and 
accumulated fewer SMA+ and OPN+ cells. In vitro, leptin-treated HSC upregulated 
OPN, SMA, collagen  and TGF mRNA by nearly 3-fold, but this effect was 
blunted by OPN loss. Inhibition of PI3K and transduction of dominant negative-Akt 
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abrogated leptin-mediated OPN induction, while constitutive active-Akt upregulated 
OPN. Finally, OPN neutralization reduced leptin-mediated fibrogenesis in both PCLS 
and MCD-fed mice. 
 
Conclusion 
OPN overexpression in NASH enhances leptin-mediated fibrogenesis via PI3K/Akt. 
OPN neutralization significantly reduces NASH fibrosis, reinforcing the potential 
utility of targeting OPN in the treatment of patients with advanced NASH.   
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Introduction 
 Individuals with nonalcoholic steatohepatitis (NASH), an advanced stage of 
nonalcoholic fatty liver disease (NAFLD), are at risk of disease progression that 
leads to liver fibrosis, cirrhosis, and cancer (1 – 4). The mechanisms which drive 
NASH progression are not entirely understood, but studies suggest that liver cell 
injury from lipotoxicity and oxidative stress triggers a fibrogenic repair response. 
Liver fibrosis develops when this injury-associated repair response becomes 
excessive or deregulated (5 – 6).  
 
 The hepatic stellate cell (HSC) or liver pericyte is the major source of 
extracellular matrix, and thus, the key effector of the repair response (7). When 
activated by cytokines (transforming growth factor ), growth factors (connective 
tissue growth factor), or morphogens (hedgehog (Hh), Wnt), quiescent HSC 
transition into motile, collagen-secreting myofibroblasts (8). HSCs are also capable 
of responding to circulating neurotransmitters and hormones (9, 10). Leptin is an 
adipocyte-derived hormone which, not only controls energy balance and food in-
take, but also modulates the liver repair response (11 – 13). Binding of leptin to HSC 
surface receptors for instance, upregulates key fibrogenic genes SMA and collagen 
11, while mice deficient in leptin (i.e. ob/ob mice) are protected against liver fibrosis 
(11, 14, 15). In humans, serum and tissue leptin levels are highly elevated in the 
obese (16 – 18), helping to explain at least in part, why obese, NAFLD individuals 
are more at risk of developing liver fibrosis. 
 
Recently, we reported that leptin-induced liver fibrosis occurs via activation of 
the Hh pathway (19) (a key morphogenic signal that regulates development as well 
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as adult tissue inflammation and fibrosis), and that upregulation of the Hh ligand and 
downstream target genes requires induction of the PI3K/Akt signaling. Hh pathway 
activation promotes transition of quiescent HSC into activated myofibroblasts (20), 
while inhibition of Hh reverses this phenotype.  Similarly, the addition of LY294002 (a 
PI3K inhibitor) or cyclopamine (a specific Hh pathway inhibitor) to leptin-treated HSC 
blocked all actions of leptin, thus revealing that the PI3K – Hh axis is necessary for 
leptin to exert its fibrogenic effects.  
 
Osteopontin (OPN) is a pro-inflammatory cytokine and matrix protein that is 
highly expressed in a variety of inflamed tissues, and plays a critical role in tissue 
repair (21, 22). OPN levels are upregulated in tissue and blood of patients with 
chronic liver disease, and have been shown to activate liver progenitors and HSC 
(23); functionally resembling Hh. Interestingly, mice with excessive Hh pathway 
activity express more liver OPN and develop worse liver fibrosis, while inhibition of 
Hh signaling (with cyclopamine) in HSC represses OPN levels (24). These results 
demonstrate that OPN is a downstream effector of Hh, and led us to hypothesize 
that OPN and leptin may interact in HSC to promote NASH progression.  
 
 Using a combination of HSC cultures and diet-induced model of NASH, 
we confirm that OPN is a downstream effector of leptin, and is required for fibrotic 
outcomes in NASH. These results are clinically important because humanized 
antibodies and aptamers which inhibit OPN actions have been developed, and may 
be used to treat patients with advanced NASH. 
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Methods 
Mice 
Lean (WT) and obese (ob/ob) mice (males, C57BL/6 background) were 
obtained from Jackson Laboratories (Bar Harbor, ME). To induce liver injury and 
fibrosis, ob/ob and WT mice (n=5/group) were fed methionine choline-deficient 
(MCD) diets (MP Biomedicals, Solon, OH) for a total of 8 weeks. In the control arm, 
ob/ob and WT mice (n=5/group) were permitted ad libitum consumption of water and 
control chow (MP Biomedicals, Solon, OH) (23, 24). 
 
In a separate study, WT mice were fed the MCD diet for 6 weeks. Sham-
aptamers or OPN-specific aptamers (see below) were administered from week 4, via 
daily tail-vein injection (200ug/injection/mouse) (25, 26).  
 
At the end of treatments, mice were sacrificed and livers harvested for 
qRTPCR and immunohistochemistry. Animal care and procedures were as per the 
NIH "Guide for the Care and Use of Laboratory Animals", and approved by relevant 
institutions: Duke University Institutional Animal Care and Use Committees, and the 
University of Calgary Animal Care Committee. 
 
Immunohistochemistry 
Liver tissue was fixed in formalin and embedded in paraffin. To quantify liver fibrosis, 
five micron sections were stained with picrosirus red (Sigma, St. Louis, MO) and 
counterstained with fast green (Sigma, St. Louis, MO). Immunohistochemical 
staining to detect OPN and SMA was performed using the DAKO Envision System 
(DAKO Corporation) according to the manufacturer’s protocol. Immunostaining were 
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performed as previously described (23). Antigen retrieval was performed by heating 
in 10 mM sodium citrate buffer (pH 6.0) or incubating with pepsin (00-3009; 
Invitrogen). Primary antibodies used were: anti-OPN (R&D; AF808) and anti-SMA 
(Abcam; ab32575). Double immunohistochemistry was performed using Vina Green, 
according to the manufacturer’s recommendation (Bio-Care Medical). Negative 
controls included liver specimens exposed to 1% bovine serum albumin instead of 
the respective primary antibodies. The proportion of tissue stained with picrosirus red 
(Sirius-Red) content, αSMA, and OPN were assessed by morphometric analysis with 
MetaView software (Universal Imaging Corp, Downtownington, PA) as previously 
described (23).  For morphometric quantification, 50 randomly chosen, 20x fields per 
section were evaluated for each mouse.  
 
Rat HSC isolation 
Primary HSCs were isolated from Sprague-Dawley rats, assessed for purity 
and viability, and seeded at a density of 3 x 102 cells/mm2 in DMEM supplemented 
with 10% fetal bovine serum (FBS) and penicillin (50 U/ml) /streptomycin (50 ug/ml) 
(20). For studies that involved treatments with leptin (100ng/ml; R&D systems, 
Minneapolis, MN) and/or adenoviral vectors, day 7 HSC cultures were cultured 
overnight in serum-depleted medium (0.1% FBS) before treatments were initiated.  
 
Adenoviral Transduction of Primary Rat HSC 
Ad5GFP, which contains the GFP gene driven by the cytomegalovirus 
promoter, was used as a control virus. The Ad5dnAkt and Ad5myrAkt viruses 
express the dominant negative and activated forms of Akt, respectively (19). Pilot 
studies demonstrated that maximally efficient transduction occurred at a multiplicity 
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of infection of 100. Subsequent experiments were carried out with this multiplicity of 
infection for 24 h; virus-containing medium was then aspirated and replaced with 
fresh medium. 
 
HSC line and treatments 
The mouse HSC line (GRX) was maintained in DMEM, 5% FBS, and 1% 
penicillin/streptomycin as described (27). Cells were treated with recombinant leptin 
(100ng/mL; R&D systems, Minneapolis, MN) for 48 hrs. For neutralization of OPN, 
40% confluent cells were treated with OPN-specific aptamers or biologically-inactive 
mutant sham aptamers (6.66ug/mL). For PI3K inhibition, LY294002 (25 uM; Cell 
Signalling Technology, Danvers, MA) was applied to cells 30 mins prior to treatment. 
AG490 (50 uM; Tocris Biosciences, Ellisville, MO) was used to inhibit JAK signaling 
(19). 
 
shRNA-mediated OPN knockdown 
GRX were seeded in 24-well plates, 5x104 per well, serum-starved (0.1% 
FBS/DMEM), and treated with 5 µg/ml polybrene (Santa Cruz, Dallas TX) in low-
serum media (0.1% FBS/DMEM) 24 h prior to infection. Cells were trypsinized and 
suspended in 250 µl media, and treated with 4 µl lentiviral particles (2x104 IFU) 
containing shRNA constructs specifically targeting OPN (Santa Cruz sc-36130-V)  or 
non-targeting scrambled control shRNA (Santa Cruz sc-108080). The plates 
containing cell and viral particle suspensions were immediately centrifuged at 750 x 
g for 30 min at 25ºC, and placed in the incubator for 48 hr. After the infection period, 
cells were then split, allowed to recover for 24 hr, then subjected to 8 µg/ml 
puromycin selection for 72 hr. 
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Transmigration and wound healing assays 
For transmigration assays, cells were cultured in the upper chamber of a 24-
well transwell system (3 µm membrane, Nunc™ Polycarbonate Membrane Inserts, 
Thermo Fisher Scientific, Loughborough, UK). After 24 h, the upper side of the 
membrane was gently wiped with a cotton bud to remove non-migrated cells, and the 
membrane was stained with crystal violet solution (1% crystal violet, 25% methanol) 
for 10 minutes, washed in PBS and allowed to air dry. Cells migrated to the bottom 
side of the membrane were visualized on an inverted microscope, and quantified 
using the average number of migrated cells per 15 randomly-selected fields. 
 
Standard wound healing assays were performed by growing cells to a confluent 
monolayer, and making a manual scratch using a P200 pipette tip. A reference mark 
was made on the wound and photographed at time 0, and compared 12 hours later. 
Wound diameters were quantified using NIH Image J version 1.48v (Rasband, W.S., 
ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, 
http://imagej.nih.gov/ij/, 1997-2012]). 
 
Semi-quantitative real-time PCR 
Total RNA was extracted from cell cultures using TRIzol® (Life Technologies, 
Carlsbad, CA) according to manufacturer’s instructions. RNA (1 µg) was reverse 
transcribed to cDNA templates using iScript cDNA synthesis kit (Bio-Rad, Hercules, 
CA). For semiquantitative RT-PCR, cDNA (25 ng) was amplified using SYBR® 
Green PCR Master Mix (Life Technologies) and oligonucleotide primers for specific 
targets sequences on an Applied Biosystems 7500 Real-Time PCR system. RT-PCR 
parameters were as follows: denaturating at 95°C for 10 minutes, followed by 40 
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cycles of denaturing at 95°C for 15 seconds and annealing/extension at 60°C for 60 
seconds. Threshold cycles (Ct) were automatically calculated by the system 
software. Target gene levels were determined relative to the S9 ribosomal protein 
housekeeping  gene using the 2–ΔΔCt method. Primer sequences are listed in 
(Supplementary Table 1) 
 
Precision Cut Liver Slice Organ Culture 
In order to study the impact of OPN neutralization in the intact liver we used a 
Krumdieck Tissue Slicer (TCS Biologicals) to cut aseptic, 250 m thick slices of live 
liver tissue, which could be studied for up to 48 hours ex-vivo. Liver tissue was 
incubated in Williams E media (Sigma) supplemented with 2% FCS, 0.1μM 
dexamethasone (Sigma) and 0.5μM insulin (Novo-Nordisk). Tissues were stimulated 
with recombinant leptin, in the presence of sham-aptamers or OPN-specific 
aptamers. At the end of treatment, liver slices were collected for RNA analysis by 
real-time PCR. Cell viability was evaluated by measuring the content of ATP with the 
ATP Bioluminescence Assay Kit CLS II (Roche, Basel, Switzerland), normalized 
against the total amount of proteins quantified by Pierce BCA Protein Assay Kit 
(Thermo Fisher Scientific, Waltham, MA). The threshold of viability is 4 nmol/mg 
protein of ATP measured 2h after recovery (i.e. time 0h in Fig 5A). 
 
Statistical Analysis 
Results are expressed as means ± SEM. Significance was established using 
the Student’s t-test and analysis of variance. Differences were considered significant 
when p < 0.05. 
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Results 
 
Leptin-deficient (ob/ob) livers contain less Osteopontin and are less fibrotic 
than control (WT) livers after MCD treatment 
Chronic exposure to the MCD diet induced comparable epithelial cell injury in 
WT (leptin-intact) and ob/ob (leptin-deficient) mice (28, 29). WT mice developed 
significant liver fibrosis in response to the MCD diet, as evidenced by ~6-fold 
accumulation of Sirius red stained collagen fibrils (Suppl Fig 1A - C), ~2.5-fold 
increase in hepatic hydroxyproline content (Suppl Fig 1D), and a 4-fold upregulation 
in collagen 11 mRNA (Suppl Fig 1E). Collagen deposition was accompanied by 
the accumulation of SMA+ cells (Suppl Fig 2A - B), OPN+ cells (Fig 1A-B), and 
induction of key fibrogenic genes, SMA (~4-fold) (Suppl Fig 2C), TGF-1 (~3-
fold)(Suppl Fig 2D), and OPN (greater than 10-fold) (Fig 1C). 
  
By contrast, fibrosis was significantly less in ob/ob mouse livers after the MCD 
diet (Suppl Fig 1): ob/ob livers contained nearly 50% fewer Sirius red stained 
collagen fibrils (Suppl Fig 1A - C), ~2.5-fold less liver hydroxyproline (Suppl Fig 
1D), ~50% less TGF-1 mRNA, and exhibited minimal induction of collagen 11, 
SMA and OPN mRNA (Suppl Fig 1E, 2C, 2D, and Fig 1C). The degree of weight 
loss however, was similar between (WT and ob/ob) MCD-fed groups. These findings 
confirm that leptin directly promotes fibrogenesis in MCD-induced NASH (11, 19, 
28). 
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OPN is a downstream effector of Leptin in Hepatic Stellate Cells (HSC) 
 Leptin is a pro-fibrogenic adipokine which directly activates HSC, the liver 
pericyte responsible for collagen matrix deposition during chronic injury (11, 12). 
Recently, we reported that OPN, a matrix protein and cytokine, could also promote 
HSC activation (23, 24). In this study, the loss of circulating leptin was directly 
associated with repressed liver OPN (Fig 1), and attenuated liver fibrogenesis 
(Suppl Fig 1, 2). These observations led us to hypothesize that leptin could regulate 
OPN expression in HSC.  
  
Recent studies revealed that HSC isolated from livers subjected to biliary or 
chemical injury upregulated OPN mRNA (Suppl Fig 3) (30). In support, we 
confirmed by double immunohistochemistry that desmin (+) HSC co-expressed OPN 
(Fig 1D). Importantly, the number of desmin / OPN double (+) HSC accumulated by 
more than 5-fold in MCD-fed mice, but this increase was almost abolished in ob/ob-
MCD mice.  
 
 To determine if leptin was directly influencing OPN expression in HSC, we 
treated the mouse HSC line, GRX, with recombinant leptin (rleptin) for 48 h; cells 
were then harvested for RNA analysis by qRTPCR. rLeptin activated HSC (Suppl 
Fig 4), upregulated OPN, and key fibrogenic markers, SMA, collagen 11, TGF 
(~2-fold) (Fig 2A – D). We next investigated if loss of OPN would inhibit leptin 
fibrogenic effects. To this end, GRX were treated with lentiviral particles which 
containin shRNA constructs specifically targeting OPN (GRX-shOPN). Compared 
with control (GRX-shScr) (GRX infected with lentiviral particles containing non-
targeting scrambled shRNA), OPN knockdown (~80%) (Suppl Fig 5) significantly 
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abrogated leptin fibrogenic effects by >90% (Fig 2). As increased cell migration is an 
important feature of activated HSC, we further examined if OPN knockdown (under 
leptin-stimulated conditions) would impair HSC migratory properties. Migration was 
assessed by semi-quantitating the dimensions of a wound dividing the confluent 
monolayer 12 h after the scratch. OPN knockdown led to ~15% less wound healing 
compared with controls (p<0.05) (Fig 2E). Comparable results observed in the 
modified cell-invasion assay (Fig 2F). OPN knockdown led to 50% fewer GRX cells 
invading across the insert membrane.  
 
 We verified these results using OPN-specific aptamers which neutralize 
circulating OPN (25, 26), in the presence of rleptin. OPN neutralization blunted 
SMA expression (Suppl Fig 6A), and significantly repressed collagen 11 and 
TGFmRNA (~50%) (Suppl Fig 6B – C). Similar to knockdown experiments, OPN 
neutralization also inhibited migratory properties of HSC, leading to impaired wound 
healing (~30%) and transmigration (~50%) across membranes (Suppl Fig 6D-E).  In 
aggregate, these results demonstrate that OPN is a downstream effector of leptin-
induced fibrogenesis, and that OPN is a potential anti-fibrotic target. 
 
OPN expression is regulated by Leptin-PI3K/Akt signaling in HSC 
 Leptin receptors couple with PI3K and activate Akt, which is required for 
leptin-associated fibrogenic effects (31, 32). Leptin activates the hedgehog (Hh) 
pathway (an important morphogenic pathway during development and adult 
fibrogenesis) in HSC, but this is blocked by LY294002, a PI3K inhibitor (19). 
Because OPN is a downstream target of the Hh pathway (24), we investigated if 
OPN could similarly be regulated by the PI3K/Akt pathway. GRX HSCs were treated 
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with leptin in the presence or absence of LY294002. LY294002 significantly 
repressed OPN mRNA by >50% (Fig 3A), and downregulated fibrogenic genes 
SMA, collagen 11, and TGFby up to 60%(Fig 3B-D). OPN knockdown in 
combination with LY294002 further enhanced repression of fibrogenic genes by an 
additional ~20% (Fig 3). 
 
To exclude the possibility that observed responses were GRX-specific, we 
repeated experiments using freshly isolated rat HSC. Comparable with GRX HSCs, 
leptin-treated, primary rat HSC upregulated OPN, SMA, and collagen 11 mRNA 
by ~2-fold (Fig 4A-C), but this effect was completely blocked in the presence of 
LY294002. OPN mRNA in particular, was repressed below basal expression. 
Adenoviral-mediated transfer of dominant negative Akt (dnAkt) similarly inhibited 
leptin-mediated changes in OPN, SMA, and collagen 11 mRNA (Fig 4A-C), but 
infection with mock adenoviral vectors (AdGFP; control) did not. By contrast, 
infection with the constitutively active Akt vector (Ad5myrAkt) induced OPN, SMA, 
and collagen 11 mRNA to levels comparable with leptin-treated cells (Fig 4).  
 
Previous studies suggested that leptin-mediated induction of the JAK/STAT 
pathway influences HSC fibrogenesis (11, 23). To clarify the role of leptin-mediated 
JAK/STAT signaling in modulating OPN expression, primary rat HSC were also 
treated with leptin in the presence or absence of AG490 (an inhibitor of JAK 
signaling). Compared with DMSO control, pre-treatment with AG490 inhibited OPN 
mRNA by ~30%.However this effect was significantly less pronounced than 
LY294002 treatment (Suppl Fig 7). These data in aggregate confirm that OPN 
expression in HSC is predominantly leptin-PI3K/Akt-regulated. 
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OPN neutralization inhibits leptin-associated fibrogenesis in precision-cut liver 
slices (PCLS) and in a mouse model of diet-induced NASH 
To validate in vitro findings, we used an established liver organ culture system 
in which precision-cut, viable mouse liver slices (PCLS) were stimulated with leptin, 
in the presence of sham- or OPN-specific aptamers. PCLS are useful because they 
can be cultured for several days and better reflect the multicellular in vivo conditions 
(33, 34). Liver slice viability was maintained as evidenced by the MTT assay (Fig 
5A). Treatment with exogenous leptin upregulated liver slices OPN mRNA by ~2-
folds (Fig 5B), and induced SMA and collagen 11mRNA by ~20% (Fig 5C-D). 
Conversely, neutralizing OPN significantly repressed OPN and collagen 11mRNA, 
even beyond basal levels. No change in total slice SMA mRNA was detected.  
 
Having demonstrated that OPN is the downstream, fibrogenic effector of 
leptin, we evaluated the impact of OPN neutralization in MCD-fed, leptin-intact (i.e. 
WT) mice. MCD-fed mice were administered sham-aptamers or OPN-specific 
aptamers via tail-vein for 2 weeks. At the end of treatment, livers were harvested and 
fibrosis assessed by qRTPCR and IHC. As expected, mice developed NASH-fibrosis 
after 5 weeks of the MCD diet (Fig 6 and Suppl Fig 1A) (23, 24). Consistent with 
cell culture and PCLS findings, OPN neutralization significantly reduced MCD diet-
induced fibrosis, as evidenced by fewer Sirius-Red stained collagen fibrils (Fig 6A - 
B), attenuated expression of fibrogenic genes, SMA, collagen 11 (Fig 6C-D), and 
reduced liver OPN expression (Fig 6E-F). 
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Discussion: 
Our study confirms that OPN is a key driver of HSC activation, and is an 
important downstream effector of leptin-induced fibrogenesis. Loss of OPN using 
OPN-specific aptamers or OPN knockdown abrogates HSC activation despite the 
presence of exogenous leptin, and these in vitro observations were recapitulated in 
the ex vivo liver slice model. Importantly, OPN neutralization in a mouse model of 
diet-induced NASH significantly reduced liver fibrosis, thereby reinforcing the 
potential utility of targeting OPN in the treatment of patients with advanced stage 
NASH.   
  
These results are consistent with findings from studies on Hh signaling in liver 
fibrosis. Both OPN and Hh are leptin-regulated, and are key effectors of leptin-
induced liver fibrosis. Although the Hh pathway is recognized for its role in embryonic 
development, recent studies also show that it regulates adult tissue repair (35). An 
over-activation of the Hh pathway leads to tissue fibrosis and cancer, while the loss 
of Hh signaling impairs wound healing (i.e. less fibrosis) (5, 36). In the liver, we and 
others recently reported that over-activation of the Hh pathway occurs during human 
NASH progression (37, 38), and that blocking Hh with the commercially available 
inhibitor, GDC0449 or cyclopamine ameliorates NASH and reduces liver fibrosis in 
mice (37, 38).  
 
 The role of OPN in liver inflammation and fibrosis is complex, and has only 
begun to be unravelled. Outside of the liver, OPN appears to exhibit fairly divergent 
roles in acute and chronic diseases. In allergic airway disease, OPN is pro-
inflammatory during primary systemic sensitization, but anti-inflammatory during 
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secondary antigenic challenge (39). Similarly, in the lpr model (autoimmune disease 
that resembles systemic lupus erythematosus), OPN mediates pathology in early 
disease, but limits exacerbation in late stage disease (40). In the liver, cumulative 
evidence suggest that targeting OPN early in disease (i.e. prevention) may result in 
worsening outcomes (41). On the other hand, the current data confirms that 
neutralizing OPN in advanced stage liver disease is beneficial, as demonstrated by 
the reduced fibrosis in an established model of NASH fibrosis.  
 
 The prevalence of NAFLD and NASH is increasing in parallel with the rising 
tide of obesity and type 2 diabetes mellitus. Studies show that obese individuals and 
those who harbour additional metabolic risk factors are at a much higher risk of 
developing NASH and /or NASH-fibrosis (42, 43). Therefore, targeting ‘modifiable’ 
mediators in these ‘at-risk’ individuals could help alleviate NASH / fibrosis burden. 
Leptin is an adipose tissue-derived hormone whose physiological role is to induce 
satiety, but levels of leptin are significantly higher in the obese, and in some with 
NAFLD (16, 17). To date, studies have evaluated the potential utility of leptin 
replacement in those with hypoleptinemia-NASH. In one study, leptin administration 
improved steatosis, but not fibrosis stage (44), and as leptin is directly pro-fibrogenic, 
it is possible that supplementation of exogenous leptin may inadvertently lead to 
worsening fibrosis. On the other hand, leptin-neutralization in those with advanced 
NASH-fibrosis (and excess leptin) may be a useful anti-fibrotic strategy (as observed 
in our study), although the likely increase in food intake and body weight (and 
metabolic risk) may well cancel out any potential clinical benefit.  
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Like leptin, plasma OPN levels are increased in the obese and in patients with 
type 2 diabetes mellitus, hypertension, and ischemic heart disease (45). More 
recently, serum OPN was also found to be associated with the onset of diabetic 
nephropathy and cardiac events (46). Thus, high levels of OPN occur in those with 
the metabolic syndrome, a risk factor for progressive NASH. Importantly, OPN 
neutralization reduces infiltration of macrophages and immune subsets into adipose 
tissues, reduces obesity-induced inflammation, and improves systemic glucose 
tolerance (47 – 50). In concert with the current findings, these data suggest that OPN 
could be an important target in the treatment of obese patients with NASH (and the 
metabolic syndrome), by reducing insulin resistance and limiting NASH-fibrosis (in 
spite of high prevailing leptin levels).  
 
In summary,  our analyses in cell-culture and mice show that OPN is leptin-
regulated, and is a key effector of leptin-induced, NASH-fibrosis. Future studies will 
be necessary to evaluate the utility of OPN neutralization in a different model of 
obesogenic NASH (such as the high-fat, high fructose / sucrose-fed model), and 
evaluate if extended periods of treatment could lead to even better anti-fibrotic 
outcomes.  
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Figure legends 
Figure 1: Osteopontin (OPN)-expressing hepatic stellate cells (HSC) 
accumulate in non-alcoholic steatohepatitis (NASH) fibrosis 
Wild type (WT) and ob/ob (leptin deficient) mice were fed control chow or the 
methionine choline deficient (MCD) diet for 8 weeks. Livers were harvested for IHC 
and qRTPCR. Representative staining are shown. (A) OPN staining. (B) OPN 
morphometry. (C) OPN mRNA; results are expressed as fold change relative to WT 
control mice. (D) OPN (brown) and Desmin (marker of HSC) (green) – double 
immunostaining (magnification x400); graph shows number of OPN / Desmin double-
positive cells per HPF (quantified by cell counting); black arrows indicate cells which 
co-express OPN and Desmin. All results are graphed as mean ± SEM; *p<0.05 vs. 
WT control mice or otherwise indicated. 
 
Figure 2: OPN loss abrogates leptin fibrogenic effects in HSC  
HSC (mouse GRX line) with OPN knockdown (shOPN) and control HSC (shScr) 
were treated with recombinant leptin (or vehicle) for 48 hours. Cells were then 
harvested and RNA analyzed by qRTPCR. (A) OPN mRNA. (B) SMA mRNA. (C) 
Collagen 11 mRNA. (D) TGFmRNA. Results are expressed as fold changes 
relative to shScr, and graphed as mean ± SEM. Wound-healing and transmigration 
studies in shOPN or shScr HSC were performed under leptin-treated conditions (E-
F). (E) Wound healing; migration was quantified by measuring the distance dividing 
the two sides of the monolayer. Mean (% wound closure) ± SEM were graphed. (F) 
Transmigration was evaluated 24 h after seeding of cells, by counting crystal violet-
stained cells on the underside membrane in 15 random HPF. Mean cell numbers ± 
SEM were graphed. *p<0.05 vs shScr or otherwise indicated. 
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Figure 3: OPN is PI3K regulated and enhances fibrogenesis in GRX HSC line  
HSC (mouse GRX line) with OPN knockdown (shOPN) and control HSC (shScr) 
were treated with recombinant leptin, with or without LY294002 (a PI3K inhibitor). 
Cells were then harvested and RNA analyzed by qRTPCR. (A) OPN mRNA. (B) 
SMA mRNA. (C) Collagen 11 mRNA. (D) TGFmRNA. Results are expressed as 
fold changes relative to shScr-Leptin, and graphed as mean ± SEM. *p<0.05 vs. 
shScr-Leptin 
 
Figure 4: OPN is a downstream target of leptin and is PI3K/Akt regulated in 
primary HSC 
Freshly isolated HSC were treated with leptin (or vehicle), with or without LY294002.  
Additional HSC were also pre-treated with Ad5dnAkt (or Ad5GFP) prior to treatment 
with leptin (100 ng/mL) or Ad5mryAkt alone. RNA was isolated and changes in gene 
expression evaluated by qRT-PCR. (A) OPN mRNA. (B) SMA mRNA. (C) Collagen 
11 mRNA. Results are expressed as fold changes relative to vehicle-treated HSC, 
and graphed as mean ± SEM. *p<0.05 vs. vehicle. 
 
Figure 5: OPN neutralization abrogates fibrogenesis in precision-cut liver 
slices (PCLS) 
Precision-cut, viable mouse liver slices (PCLS) (a liver organ culture system) were 
stimulated with leptin (or vehicle), in the presence of sham- or OPN-specific 
aptamers for 48 hours. At the end of treatment, liver slices were harvested, viability 
assessed by ATP content, and RNA analyzed by qRTPCR. (A) ATP content 
(viability) in nmol/mg protein; hashed line denotes the accepted viability threshold. 
(B) OPN mRNA. (C) SMA mRNA. (D) Collagen 11 mRNA. Results are expressed 
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as fold changes relative to vehicle-treated PCLS, and graphed as mean ± SEM. 
*p<0.05 vs. vehicle.  
 
Figure 6: OPN neutralization inhibits diet-induced NASH fibrosis in leptin-
intact mice 
Leptin-intact (WT) mice were fed control chow or the MCD diet for 6 weeks, in the 
presence of sham or OPN-aptamers. Mice were sacrificed 24 hours after final dose 
of aptamers, and livers analyzed. (A) Representative Sirius-red staining; black 
arrows indicate Sirius-red stained fibrils. Insert shows Sirius-red staining from a 
control-fed mouse. (B) Sirius-Red morphometry. (C) Collagen 11 mRNA. (D) SMA 
mRNA. Results are expressed as fold changes relative to sham-aptamer treated 
mice, and graphed as mean ± SEM. *p<0.05 vs. sham-aptamer treated mice. (E) 
Representative OPN staining; black arrows indicated OPN-positive cells. Insert 
shows OPN staining from control-fed mouse. (F) OPN morphometry.  
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Highlights 
 
 Leptin and Osteopontin are upregulated in NASH and associated with NASH 
fibrosis 
 Osteopontin is leptin-regulated and this occurs via the PI3K/Akt signaling 
pathway 
 Osteopontin knockdown and neutralization abrogates leptin-mediated 
fibrogenesis in vitro  
 OPN neutralization represses diet-induced NASH fibrosis, confirming the 
importance of OPN as a key effector of leptin-mediated fibrogenesis 
 These data confirm that OPN is an attractive therapeutic target for NASH 
fibrosis 
